Skip to main content
Loading

Innovating approaches to measure target engagement in the CNS

05 May 2026
Target Discovery
  • How can we build discovery programs for a novel CNS target?
  • What translational considerations are critical for a first-in-class CNS therapeutic?
  • How can we develop novel approaches to assess CNS target engagement in clinical trials for a first-in-class drug?
Industry Expert
Shane Hegarty, CSO - Axonis Therapeutics